Molecular heterogeneity and treatment outcome of EGFR exon 20 insertion mutations in Chinese patients with advanced non-small cell lung cancer: insights from a large-scale real-world study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Molecular heterogeneity and treatment outcome of EGFR exon 20 insertion mutations in Chinese patients with advanced non-small cell lung cancer: insights from a large-scale real-world study ; volume:24 ; number:1 ; day:14 ; month:8 ; year:2024 ; pages:1-12 ; date:12.2024
BMC cancer ; 24, Heft 1 (14.8.2024), 1-12, 12.2024
- Urheber
-
Wu, Weirui
Yu, Silin
Huang, Jinsheng
Qi, Qi
Wu, Yongyi
Dong, Jun
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-024-12773-x
- URN
-
urn:nbn:de:101:1-2411041059266.156136903234
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wu, Weirui
- Yu, Silin
- Huang, Jinsheng
- Qi, Qi
- Wu, Yongyi
- Dong, Jun
- SpringerLink (Online service)
Ähnliche Objekte (12)
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
EGFR exon 20 insertion mutations in NSCLC
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives
A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations
Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability
Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study
The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study
A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
EGFR exon 20 insertion mutations in NSCLC
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives
A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations
Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability
Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study
The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study
A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
EGFR exon 20 insertion mutations in NSCLC
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives
A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations
Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability
Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study
The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study